Edition:
United Kingdom

Savara Inc (SVRA.OQ)

SVRA.OQ on NASDAQ Stock Exchange Global Select Market

11.02USD
24 Sep 2018
Change (% chg)

$-0.19 (-1.69%)
Prev Close
$11.21
Open
$11.14
Day's High
$11.23
Day's Low
$11.00
Volume
18,217
Avg. Vol
97,020
52-wk High
$17.11
52-wk Low
$7.85

Latest Key Developments (Source: Significant Developments)

Savara Provides Positive Update On Preparations Of Molgradex
Wednesday, 25 Jul 2018 

July 25 (Reuters) - Savara Inc ::SAVARA PROVIDES POSITIVE UPDATE ON DEVELOPMENT AND COMMERCIAL PREPARATIONS OF MOLGRADEX, INCLUDING EXPANSION INTO NTM IN CF.SAVARA INC - COMPLETION OF PATIENT ENROLLMENT FOR PHASE 3 IMPALA STUDY REMAINS ON TRACK FOR Q3 2018 AND TOPLINE DATA ARE ANTICIPATED IN Q2 2019.SAVARA INC - EXPECTS SUBMISSION OF MOLGRADEX BLA, IN FIRST HALF OF 2020, WITH AN ANTICIPATED COMMERCIAL LAUNCH IN LATE 2020 OR EARLY 2021.SAVARA INC - ANNOUNCED ACQUISITION OF ASSETS OF CARDEAS PHARMA CORPORATION.  Full Article

Savara Amends Research Collaboration & License Agreement With Pari Pharma Dated Nov 7, 2014
Monday, 23 Jul 2018 

July 23 (Reuters) - Savara Inc ::SAVARA - AMENDMENT TO RESEARCH COLLABORATION & LICENSE AGREEMENT BETWEEN CO, PARI PHARMA DATED NOV 7, 2014.SAVARA - AMENDMENT ADDS NTB LUNG INFECTION TO INDICATIONS INCLUDED IN LICENSE.SAVARA INC - AMENDMENT ALLOWS CO TO ADD OTHER PULMONARY INFECTIONS TO INCLUDED INDICATIONS IN FUTURE.SAVARA - AMENDMENT EXPANDS DEVELOPMENT MILESTONES IN AGREEMENT TO INCLUDE NTM & ANY ADDITIONAL PULMONARY INDICATIONS.  Full Article

Savara Inc Files For Mixed Shelf Of Up To $250 Million
Friday, 29 Jun 2018 

June 29 (Reuters) - Savara Inc ::SAVARA INC FILES FOR MIXED SHELF OF UP TO $250 MILLION – SEC FILING.  Full Article

Savara Inc - Development Award Raised to $6.7 Mln - Sec Filing
Thursday, 30 Nov 2017 

Nov 30 (Reuters) - Savara Inc ::SAVARA- ON NOV 28 ENTERED INTO AMENDMENT EFFECTIVE SEPT 30,TO RESEARCH PROGRAM AWARD LETTER AGREEMENT BETWEEN CO, CYSTIC FIBROSIS FOUNDATION THERAPEUTICS.SAVARA INC - UNDER AMENDMENT, AMOUNT OF DEVELOPMENT AWARD AVAILABLE TO SAVARA WAS INCREASED BY $5 MILLION TO AN AGGREGATE OF $6.7 MILLION - SEC FILING.  Full Article

Savara ‍Received $5 Mln Award For Development Of Aerovanc​
Wednesday, 29 Nov 2017 

Nov 29 (Reuters) - Savara Inc ::SAVARA INC - ‍RECEIVED $5 MILLION AWARD FROM CYSTIC FIBROSIS FOUNDATION THERAPEUTICS FOR DEVELOPMENT OF AEROVANC​.  Full Article

Savara posts Q3 loss per share $0.28
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Savara Inc :Savara reports third quarter 2017 financial results and provides business update.Q3 loss per share $0.28.Q3 earnings per share view $-0.58 -- Thomson Reuters I/B/E/S.Anticipating complete enrollment in molgradex phase 3 impala study in q1 2018​.Initiating phase 2A study of Molgradex for treatment of NTM in early 2018​.Expecting top-line results from aironite phase 2 indie study in h1 2018​.Research and development expenses were $5.0 million for three-months ended September 30, 2017, compared with $2.1 million for Q3 of 2016​.  Full Article

SAVARA ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - Savara Inc ::SAVARA ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAVARA INC - ‍PRICES UNDERWRITTEN PUBLIC OFFERING OF 5.25 MILLION SHARES OF ITS COMMON STOCK AT A PRICE TO PUBLIC OF $7.85 PER SHARE​.  Full Article

Savara announces proposed public offering of common stock
Tuesday, 24 Oct 2017 

Oct 24 (Reuters) - Savara Inc :Savara announces proposed public offering of common stock.  Full Article

Savara reports completion of enrollment
Wednesday, 18 Oct 2017 

Oct 18 (Reuters) - Savara Inc ::Savara reports completion of enrollment in phase 2 clinical trial of aironite for the treatment of hfpef.Savara Inc - ‍expects that top-line results from indie-hfpef study will be available in first half of 2018​.  Full Article

BRIEF-Savara Reports Q1 Loss Per Share $0.88

* SAVARA REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE